Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.
about
Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administrationCurrent medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitationsBest of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FLDrug-related problems in patients with benign prostatic hyperplasia: a cross sectional retrospective studyTamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy.Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin.A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscleSilodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia.Silodosin in the treatment of benign prostatic hyperplasiaNew clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.The effect of competing direct-to-consumer advertising campaigns on the use of drugs for benign prostatic hyperplasia: time series analysisAlpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.Alpha-Blocker Treatment Response in Men With Lower Urinary Tract Symptoms Based on Sympathetic Activity: Prospective, Multicenter, Open-Labeled, Observational StudyOutcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)Cataract surgery in patients taking alpha-1 antagonists: know the risks, avoid the complicationsSelecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia.Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate.Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health.Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia.Current trends in the management of difficult urinary catheterizations.Novel human alpha1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological functionA survey of the FAERS database concerning the adverse event profiles of α1-adrenoreceptor blockers for lower urinary tract symptoms.Update on the use of dutasteride in the management of benign prostatic hypertrophy.Doxazosin oral intake therapy to relieve stent - related urinary symptoms and pain: a prospective, randomized, controlled studyCombination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine.Expression and function of G-protein-coupled receptors in the male reproductive tract.Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hypertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled studyCombined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Benign prostatic hyperplasia. Clinical treatment can complicate cataract surgery.Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.Combination pharmacological therapies for the management of benign prostatic hyperplasia.The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis.Update on the sexual impact of treatment for benign prostatic hyperplasia.Recent advances in the design and synthesis of prazosin derivatives.Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling.Management of benign prostatic hyperplasia with silodosin
P2860
Q24632336-5E5F145F-7004-4CD1-B73F-1AE2521923F8Q24649617-6A391499-69E8-44E9-8937-4EBD14EADDE2Q24654903-B8AEC82B-CB3C-44E7-8193-B477ED5A94D0Q28539178-6D3B3B09-0EF2-4BEE-92B8-DF7579E648BFQ33156578-C6C29E88-067D-49E9-A8FF-F5F2547D2531Q33156662-FA476589-5FE7-4BEB-9408-46F4CCBDE979Q34417223-FE9D042B-BE7A-4AAB-B9C5-7B93C78865B1Q34506119-93E2A1F0-01AE-4FB3-8CE2-86B851B5A895Q34585420-2F02E21C-2E0A-4CDD-88E2-5C50DF83A7F5Q34625490-D99B4F5D-FBD6-459B-B4AB-BCE2FB5D02A6Q34635165-7CBE47D1-DED3-48DF-9B19-15792F4D1486Q35210066-D81BEF7B-B918-469C-BFC3-3D14A5F5EECCQ35545711-9474E461-6856-43A6-AFD7-4953F80DE9BBQ35813278-CE01D5F3-707B-4105-901E-680F983AB5CCQ35919193-288F43E7-2EF4-47C4-AD35-653F525DB1C4Q36021483-391CF19A-0D53-47B1-9C61-AC60EF0236D7Q36206605-0EA3CA7F-378F-4B10-B3A9-2B96E30F6952Q36360868-47801EC9-A98E-4C86-948C-0C9AD1D5212AQ36371582-5EE73530-D46E-4A38-B8ED-A63E341662B0Q36392189-9433CD9A-E9FF-4D18-903C-C24415A2309EQ36498032-9A6E3C0B-EA35-43B8-8A22-A509AEAE93F9Q36564151-5C75425B-A4B5-4908-A608-222E7AE262E6Q36632329-51E589FE-7E16-424E-9231-CE27D5B164D7Q36909828-97FD58C9-205F-4923-99F7-28C0C72E6820Q37017292-8E673101-443B-4F03-BD26-110C4F0AF7B8Q37221786-A8E4F15E-4AB9-4649-A829-C807D6D6FF53Q37230480-2AE57EA8-A90A-4CAA-8B51-4E7BC92201E7Q37323301-31EBA398-2C54-479E-B220-73A2AC785422Q37365172-FAB4DD92-6073-437C-9F9F-4DF81F4F55EDQ37590172-347C8F79-2B06-49E2-A837-CE7EBB4FC941Q37661055-1F91E841-4A12-4EA4-8E04-D768CB91F5B7Q37790387-0A0EE1E1-D9DD-4FFC-8B00-2ED06DFE160EQ37806324-D60F8875-F6BF-4958-B6E9-38C1D228E841Q37875062-DEF5E2C6-057A-481A-9C4F-4659DE332010Q37994725-1BDA2F2E-B863-4558-885A-2302F4EF7950Q38036912-9D4B2A45-4571-4B7F-951C-8E1647171CA7Q38052091-29E569FB-ED8F-46A3-ACF6-A7BC7C056DA1Q38089804-5526B23C-1094-4AAB-BE2C-F3C9E2CAAABEQ38137877-7CECC991-9229-4DB9-BB35-CC2E79ACF86EQ38160469-594F8063-A465-4CD0-B502-DD546AC9755E
P2860
Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Alpha1-adrenergic receptors an ...... benign prostatic hyperplasia.
@ast
Alpha1-adrenergic receptors an ...... benign prostatic hyperplasia.
@en
type
label
Alpha1-adrenergic receptors an ...... benign prostatic hyperplasia.
@ast
Alpha1-adrenergic receptors an ...... benign prostatic hyperplasia.
@en
prefLabel
Alpha1-adrenergic receptors an ...... benign prostatic hyperplasia.
@ast
Alpha1-adrenergic receptors an ...... benign prostatic hyperplasia.
@en
P1476
Alpha1-adrenergic receptors an ...... benign prostatic hyperplasia.
@en
P2093
Claus G Roehrborn
Debra A Schwinn
P304
P356
10.1097/01.JU.0000097026.43866.CC
P407
P577
2004-03-01T00:00:00Z